In adult T-cell lymphoma (TCL) and cutaneous T-cell lymphoma (CTCL), IDO may also cause immunosuppression and predict prognosis, which indicates the potential of developing novel cancer immunotherapies targeting IDO [80,81]. The gene discussed is IDO1; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.